<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="the COVID-19 resource centre remains active. Abstract The outbreak of" exact="pneumonia" post="caused by a new coronavirus (SARS-CoV-2) occurred in December"/>
 <result pre="There have been other severe coronavirus outbreaks worldwide, namely, severe" exact="acute" post="respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV)."/>
 <result pre="have been other severe coronavirus outbreaks worldwide, namely, severe acute" exact="respiratory" post="syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV). Because"/>
 <result pre="been other severe coronavirus outbreaks worldwide, namely, severe acute respiratory" exact="syndrome" post="(SARS-CoV) and Middle East respiratory syndrome (MERS-CoV). Because the"/>
 <result pre="worldwide, namely, severe acute respiratory syndrome (SARS-CoV) and Middle East" exact="respiratory" post="syndrome (MERS-CoV). Because the genetic diversity of coronaviruses renders"/>
 <result pre="namely, severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory" exact="syndrome" post="(MERS-CoV). Because the genetic diversity of coronaviruses renders the"/>
 <result pre="was found to play a functional role in facilitating the" exact="infection" post="of host cells by SARS-CoV. The CyPA/CD147 interaction may"/>
 <result pre="therapeutic target for the treatment of coronavirus infection, especially coronavirus" exact="disease" post="2019 (COVID-19), and non-immunosuppressive cyclosporine analogues. Keywords cyclophilin A"/>
 <result pre="hCoV-OC43, hCoV-229E, MERS-CoV, and SARS-CoV-2) are currently reported to cause" exact="respiratory" post="diseases in humans [[2], [3], [4]]. The December 2019"/>
 <result pre="species, including Î±ã€�Î²ã€�Î³ã€�Î´, categorized based on sequence comparisons of entire" exact="viral" post="genomes. There are a total of four genera, of"/>
 <result pre="on sequence comparisons of entire viral genomes. There are a" exact="total" post="of four genera, of which only Î± and Î²"/>
 <result pre="and envelope formation, and play a significant role in subsequent" exact="viral" post="particle assembly [12]. The spike protein is essential for"/>
 <result pre="protein is essential for receptor binding [13,14]. Coronaviruses can cause" exact="respiratory" post="and intestinal infections in animals and humans [15]. According"/>
 <result pre="for receptor binding [13,14]. Coronaviruses can cause respiratory and intestinal" exact="infections" post="in animals and humans [15]. According to sequencing results,"/>
 <result pre="be a bat, but SARS-CoV may also exist through an" exact="intermediate" post="host [18]. Highly pathogenic coronavirus has been endemic three"/>
 <result pre="pathogenic diseases, including SARS-CoV and MERS-CoV, have previously caused severe" exact="respiratory" post="epidemics worldwide [19,20]. At present, there is no specific"/>
 <result pre="intensity of COVID-19. However, such drugs are far from preventing" exact="infection" post="or disease. In deciding how to treat coronavirus infection,"/>
 <result pre="immunomodulation, and signal conduction. However, CyPA is closely related to" exact="viral" post="infections, such as human immunodeficiency virus (HIV), hepatitis B"/>
 <result pre="CyPA is closely related to viral infections, such as human" exact="immunodeficiency" post="virus (HIV), hepatitis B virus (HBV), hepatitis C virus"/>
 <result pre="related to viral infections, such as human immunodeficiency virus (HIV)," exact="hepatitis" post="B virus (HBV), hepatitis C virus (HCV), rheumatoid arthritis,"/>
 <result pre="such as human immunodeficiency virus (HIV), hepatitis B virus (HBV)," exact="hepatitis C" post="virus (HCV), rheumatoid arthritis, asthma, Alzheimer's disease, and cardiovascular"/>
 <result pre="virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV)," exact="rheumatoid arthritis," post="asthma, Alzheimer's disease, and cardiovascular disease [7,8]. In addition,"/>
 <result pre="B virus (HBV), hepatitis C virus (HCV), rheumatoid arthritis, asthma," exact="Alzheimer's disease," post="and cardiovascular disease [7,8]. In addition, CyPA is associated"/>
 <result pre="hepatitis C virus (HCV), rheumatoid arthritis, asthma, Alzheimer's disease, and" exact="cardiovascular disease" post="[7,8]. In addition, CyPA is associated with hepatitis and"/>
 <result pre="C virus (HCV), rheumatoid arthritis, asthma, Alzheimer's disease, and cardiovascular" exact="disease" post="[7,8]. In addition, CyPA is associated with hepatitis and"/>
 <result pre="and cardiovascular disease [7,8]. In addition, CyPA is associated with" exact="hepatitis" post="and fibrosis caused by viral infections such as HBV,"/>
 <result pre="addition, CyPA is associated with hepatitis and fibrosis caused by" exact="viral" post="infections such as HBV, HCV and non-alcoholic fatty liver,"/>
 <result pre="CyPA is associated with hepatitis and fibrosis caused by viral" exact="infections" post="such as HBV, HCV and non-alcoholic fatty liver, as"/>
 <result pre="fibrosis caused by viral infections such as HBV, HCV and" exact="non-alcoholic fatty liver," post="as well as the generation of resistance to liver"/>
 <result pre="caused by viral infections such as HBV, HCV and non-alcoholic" exact="fatty liver," post="as well as the generation of resistance to liver"/>
 <result pre="fatty liver, as well as the generation of resistance to" exact="liver cancer" post="and liver cancer metastasis, making it a potential target"/>
 <result pre="liver, as well as the generation of resistance to liver" exact="cancer" post="and liver cancer metastasis, making it a potential target"/>
 <result pre="well as the generation of resistance to liver cancer and" exact="liver cancer" post="metastasis, making it a potential target for the treatment"/>
 <result pre="as the generation of resistance to liver cancer and liver" exact="cancer" post="metastasis, making it a potential target for the treatment"/>
 <result pre="cancer metastasis, making it a potential target for the treatment" exact="of liver" post="disease [8]. 2.2 Cyclosporine A and cyclophilins CsA was"/>
 <result pre="metastasis, making it a potential target for the treatment of" exact="liver disease" post="[8]. 2.2 Cyclosporine A and cyclophilins CsA was originally"/>
 <result pre="making it a potential target for the treatment of liver" exact="disease" post="[8]. 2.2 Cyclosporine A and cyclophilins CsA was originally"/>
 <result pre="including SARS-CoV, hCoV-229E, and hCoV-NL63, as well as the avian" exact="infectious" post="bronchitis virus [4,[32], [33], [34], [35]]. CyPA is a"/>
 <result pre="SARS-CoV, hCoV-229E, and hCoV-NL63, as well as the avian infectious" exact="bronchitis" post="virus [4,[32], [33], [34], [35]]. CyPA is a potential"/>
 <result pre="[4,35,36]. In 2011, it was reported that CsA inhibits CoV" exact="infection" post="[32]. In the same year, the Brunn team demonstrated"/>
 <result pre="culture experiments have found that CsA can strongly inhibit the" exact="viral" post="replication of SARS-CoV, MERS-CoV, hCoV-229E, poultry infectious bronchitis virus,"/>
 <result pre="strongly inhibit the viral replication of SARS-CoV, MERS-CoV, hCoV-229E, poultry" exact="infectious" post="bronchitis virus, and mouse hepatitis virus [33], but only"/>
 <result pre="inhibit the viral replication of SARS-CoV, MERS-CoV, hCoV-229E, poultry infectious" exact="bronchitis" post="virus, and mouse hepatitis virus [33], but only showed"/>
 <result pre="of SARS-CoV, MERS-CoV, hCoV-229E, poultry infectious bronchitis virus, and mouse" exact="hepatitis" post="virus [33], but only showed significant blocking in the"/>
 <result pre="have good research and development prospects. 2.4 CD147 in coronavirus" exact="infection" post="An extracellular matrix metalloproteinase inducer (CD147/EMMPRIN) is a transmembrane"/>
 <result pre="belongs to the immunoglobulin superfamily [11]. CD147 is involved in" exact="tumor" post="development, plasmodium invasion and virus infection [[12], [13], [14]]."/>
 <result pre="[11]. CD147 is involved in tumor development, plasmodium invasion and" exact="virus infection" post="[[12], [13], [14]]. CD147 can interact with cyclophilins as"/>
 <result pre="CD147 is involved in tumor development, plasmodium invasion and virus" exact="infection" post="[[12], [13], [14]]. CD147 can interact with cyclophilins as"/>
 <result pre="extracellular CyPA [15,16]. CD147 plays a critical role in the" exact="infection" post="of various viruses in the human body, such as"/>
 <result pre="cell. The CD147 molecule of the host cell can promote" exact="infection" post="of the host cell by the HIV-1 virus through"/>
 <result pre="HIV-1 virus through interaction with the virus-associated CyPA. During SARS-CoV" exact="infection" post="of host cells, the CD147 molecule works via a"/>
 <result pre="and that CD147 has a critical role in promoting the" exact="infection" post="of host cells by the virus. Surface plasmon resonance"/>
 <result pre="N protein of SARS-CoV, CD147 plays a role in facilitating" exact="infection" post="of host cells by SARS-CoV [18,19]. There are currently"/>
 <result pre="shows that CD147 can be a novel route for the" exact="infection" post="of SARS-CoV-2 as well as a novel target for"/>
 <result pre="CD147 in SARS-CoV-2 infection, and CyPA inhibitors may inhibit the" exact="infection" post="of SARS-CoV-2 by blocking the infection route. CyPA/CD147 interaction"/>
 <result pre="inhibitors may inhibit the infection of SARS-CoV-2 by blocking the" exact="infection" post="route. CyPA/CD147 interaction is also related to other diseases."/>
 <result pre="many animal models. Studies on synovial macrophages in patients with" exact="rheumatoid arthritis" post="have reported that the expression of CyPA and CD147"/>
 <result pre="animal models. Studies on synovial macrophages in patients with rheumatoid" exact="arthritis" post="have reported that the expression of CyPA and CD147"/>
 <result pre="important. CyPA and CD147 have higher levels of expression in" exact="pancreatic cancer" post="tissues, in which CyPA is found in a dose-dependent"/>
 <result pre="CyPA and CD147 have higher levels of expression in pancreatic" exact="cancer" post="tissues, in which CyPA is found in a dose-dependent"/>
 <result pre="CyPA is found in a dose-dependent manner. This proliferation of" exact="pancreatic cancer" post="cells can be effectively blocked by CD147 antibody [25]."/>
 <result pre="is found in a dose-dependent manner. This proliferation of pancreatic" exact="cancer" post="cells can be effectively blocked by CD147 antibody [25]."/>
 <result pre="the replication of SARS-CoV intracellularly, but also may inhibit the" exact="infection" post="of SARS-CoV into host cells via interacting with CD147."/>
 <result pre="Image 1 Norvatis Adult, non-immunocompromised patients with severe, recalcitrant, plaque" exact="psoriasis" post="who have failed to respond to at least one"/>
 <result pre="psoriasis who have failed to respond to at least one" exact="systemic" post="therapy (e.g., PUVA, retinoids, or methotrexate) and in patients"/>
 <result pre="PUVA, retinoids, or methotrexate) and in patients for whom other" exact="systemic" post="therapies are contraindicated or cannot be tolerated CsA inhibits"/>
 <result pre="coronaviruses. Treatment of infected cells with 16â€¯Î¼M CsA strongly reduced" exact="viral" post="and reporter gene expression of SARS-CoVâ€&quot;GFP, the amount of"/>
 <result pre="SARS-CoVâ€&quot;GFP, the amount of dsRNA in infected cells, and the" exact="viral" post="titer in culture supernatants (by &amp;gt;3 logs) [32]. Indication"/>
 <result pre="(by &amp;gt;3 logs) [32]. Indication mentioned previously: On marketHepatitis C" exact="viral" post="infection:Phase IV completed Alisporivir Image 2 Norvatis Hepatitis C;"/>
 <result pre="marketHepatitis C viral infection:Phase IV completed Alisporivir Image 2 Norvatis" exact="Hepatitis" post="C; chronic hepatitis C Alisporivir block SARS-CoV and MERS-CoV"/>
 <result pre="viral infection:Phase IV completed Alisporivir Image 2 Norvatis Hepatitis C;" exact="chronic hepatitis C" post="Alisporivir block SARS-CoV and MERS-CoV replication. Combination treatment with"/>
 <result pre="infection:Phase IV completed Alisporivir Image 2 Norvatis Hepatitis C; chronic" exact="hepatitis C" post="Alisporivir block SARS-CoV and MERS-CoV replication. Combination treatment with"/>
 <result pre="ribavirin increases the anti-MERS-CoV activity in vitro[39]. Gastrointestinal disorders: PreclinicalChronic" exact="hepatitis C" post="virus infection/hepatitis C viral infection: Phase III completed NIM811"/>
 <result pre="in vitro[39]. Gastrointestinal disorders: PreclinicalChronic hepatitis C virus infection/hepatitis C" exact="viral" post="infection: Phase III completed NIM811 Image 3 Novartis Hepatitis"/>
 <result pre="C viral infection: Phase III completed NIM811 Image 3 Novartis" exact="Hepatitis" post="C; HIV-1 infection Induces a dose-dependent reduction of HCV"/>
 <result pre="Phase III completed NIM811 Image 3 Novartis Hepatitis C; HIV-1" exact="infection" post="Induces a dose-dependent reduction of HCV RNA in the"/>
 <result pre="replicon cells with an IC50 of 0.66â€¯Î¼M at 48â€¯h [40]." exact="Chronic" post="hepatitis C genotype-1 relapse: Phase II completed SCY-635 Image"/>
 <result pre="cells with an IC50 of 0.66â€¯Î¼M at 48â€¯h [40]. Chronic" exact="hepatitis C" post="genotype-1 relapse: Phase II completed SCY-635 Image 4 SCYNEXIS,"/>
 <result pre="genotype-1 relapse: Phase II completed SCY-635 Image 4 SCYNEXIS, Inc." exact="Hepatitis" post="C; hepatitis B Show inhibition at 0.07, 0.08, and"/>
 <result pre="Phase II completed SCY-635 Image 4 SCYNEXIS, Inc. Hepatitis C;" exact="hepatitis" post="B Show inhibition at 0.07, 0.08, and 0.15â€¯Î¼M, respectively,"/>
 <result pre="and 0.15â€¯Î¼M, respectively, in the HCV subgenomic replicon system [41]." exact="Hepatitis" post="C: Phase IIHepatitis B: No development reported STG-175 Image"/>
 <result pre="No development reported STG-175 Image 5 S &amp;amp; T Global" exact="Hepatitis" post="B STG-175 inhibits at a nanomolar range the replication"/>
 <result pre="GT1b (EC50â€¯=â€¯15.1â€¯nM), GT2a (EC50â€¯=â€¯11.5â€¯nM), GT3a (EC50â€¯=â€¯38.9â€¯nM) and GT4a (EC50â€¯=â€¯15.2â€¯nM) [42]." exact="Hepatitis" post="B: Preclinical CRV431 Image 6 Hepion Pharmaceuticals Hepatitis B"/>
 <result pre="(EC50â€¯=â€¯15.2â€¯nM) [42]. Hepatitis B: Preclinical CRV431 Image 6 Hepion Pharmaceuticals" exact="Hepatitis" post="B In a transgenic mouse model, CRV431 (10â€¯mg/kg/day) reduced"/>
 <result pre="(50â€¯mg/kg) reduced the mean HBV DNA level by 91% [44]." exact="Hepatitis" post="B: Phase I/IIHepatitis D; liver cancer; non-alcoholic fatty liver"/>
 <result pre="DNA level by 91% [44]. Hepatitis B: Phase I/IIHepatitis D;" exact="liver cancer;" post="non-alcoholic fatty liver disease; non-alcoholic steatohepatitis: PreclinicalCoronavirus infections; hepatitis"/>
 <result pre="by 91% [44]. Hepatitis B: Phase I/IIHepatitis D; liver cancer;" exact="non-alcoholic fatty liver" post="disease; non-alcoholic steatohepatitis: PreclinicalCoronavirus infections; hepatitis C; HIV-1 infections:"/>
 <result pre="91% [44]. Hepatitis B: Phase I/IIHepatitis D; liver cancer; non-alcoholic" exact="fatty liver disease;" post="non-alcoholic steatohepatitis: PreclinicalCoronavirus infections; hepatitis C; HIV-1 infections: Discontinued"/>
 <result pre="[44]. Hepatitis B: Phase I/IIHepatitis D; liver cancer; non-alcoholic fatty" exact="liver disease;" post="non-alcoholic steatohepatitis: PreclinicalCoronavirus infections; hepatitis C; HIV-1 infections: Discontinued"/>
 <result pre="liver cancer; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis: PreclinicalCoronavirus infections;" exact="hepatitis C;" post="HIV-1 infections: Discontinued CPI-431-32 Image 7 Ciclofilin Pharmaceuticals Inc"/>
 <result pre="C; HIV-1 infections: Discontinued CPI-431-32 Image 7 Ciclofilin Pharmaceuticals Inc" exact="Hepatitis" post="B Effectively inhibits HIV-1/HCV co-infection; also shows efficacy against"/>
 <result pre="variants. A daily CPI-431-32 dose of 0.5â€¯Î¼M is used. [43]." exact="Hepatitis" post="B; neurological disorders; reperfusion injury:Preclinical-discontinuedHIV-1, HCV: PreclinicalA study in"/>
 <result pre="injury:Preclinical-discontinuedHIV-1, HCV: PreclinicalA study in healthy volunteers and patients with" exact="chronic hepatitis" post="B:Phase I: Active, not recruiting It was reported that"/>
 <result pre="HCV: PreclinicalA study in healthy volunteers and patients with chronic" exact="hepatitis" post="B:Phase I: Active, not recruiting It was reported that"/>
 <result pre="could be a candidate drug for the treatment of CoV" exact="infection" post="in humans [4,36]. CsA and its derivatives interrupt the"/>
 <result pre="the replication of MERS and SARS CoVs, and in cell-based" exact="infection" post="models, ribavirin further enhances alisporivir's antiviral effect [39]. 3"/>
 <result pre="recent SARS-CoV-2 epidemic, there have been three outbreaks of severe" exact="infectious diseases" post="caused by CoVs, which require high attention. In recent"/>
 <result pre="be a feasible part of treatment. There is still no" exact="complete" post="validation of the inhibitory effect of non-immunosuppressive cyclophilin inhibitors"/>
 <result pre="1PerlmanS.NetlandJ.Coronaviruses post-SARS: update on replication and pathogenesisNat Rev Microbiol76200943945019430490 2ChanJ.F.-W.YuanS.KokK.-H.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="on replication and pathogenesisNat Rev Microbiol76200943945019430490 2ChanJ.F.-W.YuanS.KokK.-H.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="discovery and therapeutic optionsNat Rev Drug Discov155201632734726868298 4Von BrunnA.CiesekS.Von BrunnB.Genetic" exact="deficiency" post="and polymorphisms of cyclophilin A reveal its essential role"/>
 <result pre="229E replicationCurr Opin Virol142015566126318518 5ZhuN.ZhangD.WangW.A Novel Coronavirus from Patients with" exact="Pneumonia" post="in China, 2019N Engl J Med3828202072773331978945 6HuangC.WangY.LiX.Clinical features of"/>
 <result pre="7ZhuD.WangZ.ZhaoJ.-J.The Cyclophilin A-CD147 complex promotes the proliferation and homing of" exact="multiple myeloma" post="cellsNat Med216201557258026005854 8NaoumovN.V.Cyclophilin inhibition as potential therapy for liver"/>
 <result pre="Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple" exact="myeloma" post="cellsNat Med216201557258026005854 8NaoumovN.V.Cyclophilin inhibition as potential therapy for liver"/>
 <result pre="11PaulesC.I.MarstonH.D.FauciA.S.Coronavirus Infections-More Than Just the Common ColdJAMA202010.1001/jama.2020.0757 12TsengY.-T.WangS.-M.HuangK.-J.Self-assembly of severe" exact="acute" post="respiratory syndrome coronavirus membrane proteinJ Biol Chem285172010128621287220154085 13LiF.Structure, Function,"/>
 <result pre="Infections-More Than Just the Common ColdJAMA202010.1001/jama.2020.0757 12TsengY.-T.WangS.-M.HuangK.-J.Self-assembly of severe acute" exact="respiratory" post="syndrome coronavirus membrane proteinJ Biol Chem285172010128621287220154085 13LiF.Structure, Function, and"/>
 <result pre="Than Just the Common ColdJAMA202010.1001/jama.2020.0757 12TsengY.-T.WangS.-M.HuangK.-J.Self-assembly of severe acute respiratory" exact="syndrome" post="coronavirus membrane proteinJ Biol Chem285172010128621287220154085 13LiF.Structure, Function, and Evolution"/>
 <result pre="of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and" exact="viral" post="nucleocapsid protein during human coronavirus 229E replicationAntiviral Res173202010462031634494 36NigroP.PompilioG.CapogrossiM.C.Cyclophilin"/>
 <result pre="MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus" exact="infection" post="in a mouse modelVirus Res228201771327840112 40MaS.BoernerJ.E.TiongyipC.NIM811, a cyclophilin inhibitor,"/>
 <result pre="40MaS.BoernerJ.E.TiongyipC.NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against" exact="hepatitis C" post="virus alone or in combination with alpha interferonAntimicrob Agents"/>
 <result pre="novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of" exact="hepatitis C" post="virus RNA replication in vitroAntimicrob Agents Chemother542201066067219933795 42GallayP.A.ChatterjiU.BobardtM.D.Characterization of"/>
 <result pre="43GallayP.A.BobardtM.D.ChatterjiU.The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1" exact="Infections" post="via a Similar Mechanism of ActionPLoS One1082015e0134707 44GallayP.UreD.BobardtM.The cyclophilin"/>
 <result pre="HBsAg in transgenic micePLoS One1462019e0217433 45Sofitcl.BrilletR.BerryF.Antimicrob Agents Chemother202011010.1128/AAC.00876-20 46GorbalenyaA.E.BakerS.C.BaricR.S.The species" exact="Severe" post="acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it"/>
 <result pre="in transgenic micePLoS One1462019e0217433 45Sofitcl.BrilletR.BerryF.Antimicrob Agents Chemother202011010.1128/AAC.00876-20 46GorbalenyaA.E.BakerS.C.BaricR.S.The species Severe" exact="acute" post="respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat"/>
 <result pre="transgenic micePLoS One1462019e0217433 45Sofitcl.BrilletR.BerryF.Antimicrob Agents Chemother202011010.1128/AAC.00876-20 46GorbalenyaA.E.BakerS.C.BaricR.S.The species Severe acute" exact="respiratory" post="syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat Microbiol.5202053654432123347"/>
</results>
